Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (134)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jensen, T.
Right arrow Articles by Koch, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, T.
Right arrow Articles by Koch, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 19, 831-838
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

Tim Jensena,, Svend S. Pedersenb, Susanne Garnea, Carsten Heilmanna, Niels Høibyb and Christian Kocha

aDepartment of Paediatrics Rigshospitalet, Copenhagen bDepartment of Clinical Microbiology at Rigshospitalet Statens Seruminstitut, Copenhagen, Denmark

accepted 22 December 1986

Tim Jensen, Department of Paediatrics, afsnit 5002, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.

Forty patients with cystic fibrosis and chronic broncho-pulmonary Pseudomonas aeruginosa infection entered a prospective double-blind placebo-controlled study of colistin inhalation. Active treatment consisted of inhalation of colistin one million units twice daily for three months and was compared to placebo inhalations of isotonic saline.

Significantly more patients in the colistin inhalation group completed the study as compared to the placebo group (18 versus 11). Colistin treatment was superior to placebo treatment in terms of a significantly better clinical symptom score, maintenance of pulmonary function and inflammatory parameters.

We recommend colistin inhalation therapy for cystic fibrosis patients with chronic P. aeruginosa lung infection as a supplementary treatment to frequent courses of intravenous anti-pseudomonas chemotherapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Sun, A. Negrea, M. Rhen, and D. I. Andersson
Genetic Analysis of Colistin Resistance in Salmonella enterica Serovar Typhimurium
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2298 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. J. Wallace, J. Li, Craig. R. Rayner, K. Coulthard, and R. L. Nation
Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3047 - 3051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. A. Flume, B. P. O'Sullivan, K. A. Robinson, C. H. Goss, P. J. Mogayzel Jr., D. B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, et al.
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 957 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. B. Shirk, K. R. Donahue, and J. Shirvani
Unlabeled uses of nebulized medications.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. A Hakeam and A. M Almohaizeie
Hypotension Following Treatment with Aerosolized Colistin in a Patient with Multidrug-Resistant Pseudomonas aeruginosa
Ann. Pharmacother., September 1, 2006; 40(9): 1677 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Mulheran, P. Hyman-Taylor, K. H.-V. Tan, S. Lewis, D. Stableforth, A. Knox, and A. Smyth
Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2293 - 2299.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Koeman, A. J. A. M. van der Ven, E. Hak, H. C. A. Joore, K. Kaasjager, A. G. A. de Smet, G. Ramsay, T. P. J. Dormans, L. P. H. J. Aarts, E. E. de Bel, et al.
Oral Decontamination with Chlorhexidine Reduces the Incidence of Ventilator-associated Pneumonia
Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1348 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. E. Falagas, S. K. Kasiakou, S. Tsiodras, and A. Michalopoulos
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Clin. Med. Res., June 1, 2006; 4(2): 138 - 146.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann
Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Zhang, J. Parente, S. M. Harris, D. E. Woods, R. E. W. Hancock, and T. J. Falla
Antimicrobial Peptide Therapeutics for Cystic Fibrosis
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2921 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. A. LoBue
Inhaled Tobramycin: Not Just for Cystic Fibrosis Anymore?
Chest, April 1, 2005; 127(4): 1098 - 1101.
[Full Text] [PDF]

Home page
 ChestHome page
G. A. Alothman, B. Ho, M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Chest, February 1, 2005; 127(2): 522 - 529.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
D. Berlana, J. M. Llop, E. Fort, M. B. Badia, and R. Jodar
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 39 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
S P Conway
Nebulized antibiotic therapy: the evidence
Chronic Respiratory Disease, January 1, 2005; 2(1): 35 - 41.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. Jain and L. H Danziger
Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians
Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. L. Gibson, J. L. Burns, and B. W. Ramsey
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M.E. Hodson, C.G. Gallagher, and J.R.W. Govan
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Eur. Respir. J., September 1, 2002; 20(3): 658 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. B. Lyczak, C. L. Cannon, and G. B. Pier
Lung Infections Associated with Cystic Fibrosis
Clin. Microbiol. Rev., April 1, 2002; 15(2): 194 - 222.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. Schulin
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany
J. Antimicrob. Chemother., February 1, 2002; 49(2): 403 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
U. S. Sajjan, L. T. Tran, N. Sole, C. Rovaldi, A. Akiyama, P. M. Friden, J. F. Forstner, and D. M. Rothstein
P-113D, an Antimicrobial Peptide Active against Pseudomonas aeruginosa, Retains Activity in the Presence of Sputum from Cystic Fibrosis Patients
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3437 - 3444.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
C. A. Robinson and R. J. Kuhn
Management of Pulmonary Disease in Patients with Cystic Fibrosis
Journal of Pharmacy Practice, June 1, 2001; 14(3): 207 - 227.
[Abstract] [PDF]

Home page
 ChestHome page
S. L. Katz, S. L. Ho, and A. L. Coates
Nebulizer Choice for Inhaled Colistin Treatment in Cystic Fibrosis
Chest, January 1, 2001; 119(1): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. G. Prober, P. D. Walson, J. Jones, and the Committee on Infectious Diseases and Committee
Technical Report: Precautions Regarding the Use of Aerosolized Antibiotics
Pediatrics, December 1, 2000; 106(6): 89e - 89.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. H. HAMER
Treatment of Nosocomial Pneumonia and Tracheobronchitis Caused by Multidrug-Resistant Pseudomonas aeruginosa with Aerosolized Colistin
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 328 - 330.
[Abstract] [Full Text]

Home page
 ThoraxHome page
N HØIBY and C KOCH
Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis
Thorax, May 1, 2000; 55(5): 349 - 350.
[Full Text]

Home page
 ChestHome page
P. W. Campbell III and L. Saiman
Use of Aerosolized Antibiotics in Patients With Cystic Fibrosis
Chest, September 1, 1999; 116(3): 775 - 788.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. E. W. Hancock and D. S. Chapple
Peptide Antibiotics
Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1317 - 1323.
[Full Text]

Home page
 Arch. Dis. Child.Home page
S P CONWAY
Evidence for using nebulised antibiotics in cystic fibrosis
Arch. Dis. Child., April 1, 1999; 80(4): 307 - 309.
[Full Text]

Home page
 J Antimicrob ChemotherHome page
S. M. McAllister, H. O. Alpar, and M. R. W. Brown
Antimicrobial properties of liposomal polymyxin B
J. Antimicrob. Chemother., February 1, 1999; 43(2): 203 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
E Ring, E Eber, W Erwa, and M S Zach
Urinary N-acetyl-beta -D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation
Arch. Dis. Child., June 1, 1998; 78(6): 540 - 543.
[Abstract] [Full Text]

Home page
 ThoraxHome page
R. Wilson and R. B Dowling
Pseudomonas aeruginosa and other related species
Thorax, March 1, 1998; 53(3): 213 - 219.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. BISGAARD, S. S. PEDERSEN, K. G. NIELSEN, M. SKOV, E. M. LAURSEN, G. KRONBORG, C. M. REIMERT, N. H OIBY, and C. KOCH
Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic Bronchopulmonary Pseudomonas aeruginosa Infection
Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1190 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. W. Ramsey
Management of Pulmonary Disease in Patients with Cystic Fibrosis
N. Engl. J. Med., July 18, 1996; 335(3): 179 - 188.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.